US6753349B1 - Method of preparing valproinic acid compounds - Google Patents

Method of preparing valproinic acid compounds Download PDF

Info

Publication number
US6753349B1
US6753349B1 US10/129,023 US12902302A US6753349B1 US 6753349 B1 US6753349 B1 US 6753349B1 US 12902302 A US12902302 A US 12902302A US 6753349 B1 US6753349 B1 US 6753349B1
Authority
US
United States
Prior art keywords
salt
valproic acid
alkaline earth
alkali metal
earth metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/129,023
Inventor
Christian Weh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag AG
Original Assignee
Cilag AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag AG filed Critical Cilag AG
Assigned to CILAG AG reassignment CILAG AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WEH, CHRISTIAN
Application granted granted Critical
Publication of US6753349B1 publication Critical patent/US6753349B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to a method of preparing oligomeric valproic acid compounds, especially a method of preparing selected oligomeric valproic acid compounds, without the addition of a solvent.
  • Valproic acid is also known as 2-propylpentanoic acid, 2-propylvaleric acid or di-n-propylacetic acid. The term valproic acid is used hereafter.
  • Valproic acid and oligomeric compounds are known per se. Valproic acid, sodium valproate and the oligomeric 1:1 compound of sodium valproate and valproic acid, called divalproex sodium, are active ingredients for the medicinal treatment of epileptic fits, cramp and migraine. Valproic acid is liquid at room temperature and is therefore unsuitable for the preparation of solid pharmaceutical formulations such as tablets. Sodium valproate is solid at room temperature but is very hygroscopic, which makes it very difficult to prepare solid pharmaceutical formulations for oral administration. Divalproex sodium is less hygroscopic, but the compound has a tendency to form lumps and become encrusted on prolonged storage.
  • oligomeric valproic acid compounds described below represent possible ways of formulating valproic acid which exhibit said disadvantages to a considerably reduced extent, if at all. It is therefore of interest to be able to prepare such compounds in the simplest possible manner.
  • oligomeric compounds of sodium valproate and valproic acid can be prepared without the addition of a solvent to the reaction mixture, which is ecologically and economically advantageous.
  • the method according to the invention also has the advantage that lengthy and energy-intensive drying processes can be avoided and environmentally relevant aspects, for example minimization of resources, saving of raw materials and energy or waste reduction, can be taken into account.
  • the method according to the invention enables the active ingredients to be prepared without drying, under mild conditions and with the avoidance of decomposition processes due to temperature.
  • the method according to the invention offers doctors and patients the opportunity to select their preferred active ingredients from the large number of different, equally potent compounds of valproic acid and valproic acid salts, all of these active ingredients having been prepared by processes identical per se.
  • One particular advantage of the present invention is that the method according to the invention makes it possible to prepare compounds with selected stoichiometries, i.e., with selected proportions of valproic acid salt and valproic acid, which has hitherto been impossible for these compositions via crystallization from organic solvents.
  • Another advantage of the method according to the invention is that it dispenses with the use of sodium valproate as a hygroscopic sodium source.
  • the present invention relates in particular to a method of preparing compounds containing at least one molecule of valproic acid salt and at least one molecule of valproic acid, the valproic acid salt being an alkali metal or alkaline earth metal salt, characterized in that valproic acid is reacted directly with the calculated amount of the appropriate alkali metal carbonate or alkaline earth metal carbonate and/or the calculated amount of the appropriate alkali metal bicarbonate or alkaline earth metal bicarbonate, without the addition of a solvent, at a temperature above the melting point of valproic acid.
  • the reaction temperature is preferably 50° C. to 250° C. and particularly preferably 70° C. to 180° C., the carbon dioxide and water formed in the reaction being removed continuously from the reaction mixture.
  • the valproic acid reacts directly and completely with the carbonate (e.g. Na 2 CO 3 , CaCO 3 ) or the bicarbonate (e.g. LiHCO 3 , Ca(HCO 3 ) 2 ) to form CO 2 and water. If the compound is to be prepared as a hydrate, the calculated amount of water is added to the product, preferably after the reaction has ended.
  • An alkali metal salt of valproic acid is preferably the lithium, sodium, potassium or rubidium salt and particularly preferably the sodium or potassium salt.
  • An alkaline earth metal salt of valproic acid is preferably the magnesium, calcium, strontium or barium salt and particularly preferably the magnesium or calcium salt.
  • the compounds according to the present invention which contain at least one molecule of valproic acid salt and at least one molecule of valproic acid, have general formula (I):
  • Me is Li + , Na + , K + , Rb + , Mg 2+ , Ca 2+ , Sr 2+ or Ba 2+ , preferably Na + , K +, Mg 2+ or Ca 2+ ;
  • n is an integer from 1 to 10, preferably from 1 to 6,
  • n is an integer from 1 to 9, preferably from 1 to 3, and the ratio m:n is from 1:1 to 6:1, preferably 1:1 to 5:3 and particularly preferably 1:1, 4:3 or 2:1; and
  • x is zero, 1 or 2, preferably zero or 1.
  • Examples of compounds of formula (I) are: 2-propylpentanoic acid (2:1) sodium salt; 2-propylpentanoic acid (2:1) sodium salt monohydrate and dihydrate; 2-propylpentanoic acid (3:2) sodium salt; 2-propylpentanoic acid (4:3) sodium salt; 2-propylpentanoic acid (4:3) sodium salt monohydrate; 2-propylpentanoic acid (5:3) sodium salt; 2-propylpentanoic acid (7:6) sodium salt and the monohydrate and dihydrate; preferably 2-propylpentanoic acid (m+n:m) sodium salt xH 2 O in which m+n is an integer from 3 to 10, m is 1 to (m+n ⁇ 1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) lithium salt; 2-propylpentanoic acid (2:1) lithium salt; 2-propylpentanoic acid (2:1) lithium salt

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a method for producing compounds which contain at least one molecule valproic acid salt and at least one molecule valproic acid. The valproic acid salt represents alkali or alkaline earth salt. Valproic acid is directly converted with the calculated amount of the corresponding alkali carbonate or earth alkaline carbonate and/or the calculated amount of the corresponding alkali bicarbonate or earth alkaline bicarbonate without adding a solvent and at a temperature that is higher than the melting temperature of valproic acid.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application No. PCT/CH00/00578, filed on Oct. 31, 2000, which claims priority to Swiss Patent Application No. CH 1997/99, filed Nov. 2, 1999, and which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to a method of preparing oligomeric valproic acid compounds, especially a method of preparing selected oligomeric valproic acid compounds, without the addition of a solvent. Valproic acid is also known as 2-propylpentanoic acid, 2-propylvaleric acid or di-n-propylacetic acid. The term valproic acid is used hereafter.
BACKGROUND OF THE INVENTION
Valproic acid and oligomeric compounds are known per se. Valproic acid, sodium valproate and the oligomeric 1:1 compound of sodium valproate and valproic acid, called divalproex sodium, are active ingredients for the medicinal treatment of epileptic fits, cramp and migraine. Valproic acid is liquid at room temperature and is therefore unsuitable for the preparation of solid pharmaceutical formulations such as tablets. Sodium valproate is solid at room temperature but is very hygroscopic, which makes it very difficult to prepare solid pharmaceutical formulations for oral administration. Divalproex sodium is less hygroscopic, but the compound has a tendency to form lumps and become encrusted on prolonged storage.
SUMMARY OF THE INVENTION
The oligomeric valproic acid compounds described below, with different stoichiometries and solvates, represent possible ways of formulating valproic acid which exhibit said disadvantages to a considerably reduced extent, if at all. It is therefore of interest to be able to prepare such compounds in the simplest possible manner. In particular, it has been found that oligomeric compounds of sodium valproate and valproic acid can be prepared without the addition of a solvent to the reaction mixture, which is ecologically and economically advantageous.
The method according to the invention also has the advantage that lengthy and energy-intensive drying processes can be avoided and environmentally relevant aspects, for example minimization of resources, saving of raw materials and energy or waste reduction, can be taken into account. In particular, the method according to the invention enables the active ingredients to be prepared without drying, under mild conditions and with the avoidance of decomposition processes due to temperature.
At the same time, the method according to the invention offers doctors and patients the opportunity to select their preferred active ingredients from the large number of different, equally potent compounds of valproic acid and valproic acid salts, all of these active ingredients having been prepared by processes identical per se.
One particular advantage of the present invention is that the method according to the invention makes it possible to prepare compounds with selected stoichiometries, i.e., with selected proportions of valproic acid salt and valproic acid, which has hitherto been impossible for these compositions via crystallization from organic solvents. Another advantage of the method according to the invention is that it dispenses with the use of sodium valproate as a hygroscopic sodium source.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention relates in particular to a method of preparing compounds containing at least one molecule of valproic acid salt and at least one molecule of valproic acid, the valproic acid salt being an alkali metal or alkaline earth metal salt, characterized in that valproic acid is reacted directly with the calculated amount of the appropriate alkali metal carbonate or alkaline earth metal carbonate and/or the calculated amount of the appropriate alkali metal bicarbonate or alkaline earth metal bicarbonate, without the addition of a solvent, at a temperature above the melting point of valproic acid.
The reaction temperature is preferably 50° C. to 250° C. and particularly preferably 70° C. to 180° C., the carbon dioxide and water formed in the reaction being removed continuously from the reaction mixture. The valproic acid reacts directly and completely with the carbonate (e.g. Na2CO3, CaCO3) or the bicarbonate (e.g. LiHCO3, Ca(HCO3)2) to form CO2 and water. If the compound is to be prepared as a hydrate, the calculated amount of water is added to the product, preferably after the reaction has ended.
An alkali metal salt of valproic acid is preferably the lithium, sodium, potassium or rubidium salt and particularly preferably the sodium or potassium salt. An alkaline earth metal salt of valproic acid is preferably the magnesium, calcium, strontium or barium salt and particularly preferably the magnesium or calcium salt.
The compounds according to the present invention, which contain at least one molecule of valproic acid salt and at least one molecule of valproic acid, have general formula (I):
[(CH3CH2CH2)2CH—C(O)OMe]m.[(CH3CH2CH2)2CH—C(O)OH]n.xH2O  (I)
in which
Me is Li+, Na+, K+, Rb+, Mg2+, Ca2+, Sr2+ or Ba2+, preferably Na+, K+, Mg 2+ or Ca2+;
m is an integer from 1 to 10, preferably from 1 to 6,
n is an integer from 1 to 9, preferably from 1 to 3, and the ratio m:n is from 1:1 to 6:1, preferably 1:1 to 5:3 and particularly preferably 1:1, 4:3 or 2:1; and
x is zero, 1 or 2, preferably zero or 1.
In the Examples which follow, the numbers in brackets indicate the ratio (m+n:m) in each case. Examples of compounds of formula (I) are: 2-propylpentanoic acid (2:1) sodium salt; 2-propylpentanoic acid (2:1) sodium salt monohydrate and dihydrate; 2-propylpentanoic acid (3:2) sodium salt; 2-propylpentanoic acid (4:3) sodium salt; 2-propylpentanoic acid (4:3) sodium salt monohydrate; 2-propylpentanoic acid (5:3) sodium salt; 2-propylpentanoic acid (7:6) sodium salt and the monohydrate and dihydrate; preferably 2-propylpentanoic acid (m+n:m) sodium salt xH2O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) lithium salt; 2-propylpentanoic acid (2:1) lithium salt monohydrate and dihydrate; 2-propylpentanoic acid (4:3) lithium salt; 2-propylpentanoic acid (4:3) lithium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) lithium salt xH2O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) potassium salt; 2-propylpentanoic acid (2:1) potassium salt monohydrate; 2-propylpentanoic acid (3:2) potassium salt; 2-propylpentanoic acid (4:3) potassium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) potassium salt xH2O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) rubidium salt; 2-propylpentanoic acid (2:1) rubidium salt monohydrate; 2-propylpentanoic acid (3:2) rubidium salt; 2-propylpentanoic acid (4:3) rubidium salt monohydrate; 2-propylpentanoic acid (m+n:m) rubidium salt xH2O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; preferably 2-propylpentanoic acid (2:1) magnesium salt; 2-propylpentanoic acid (2:1) magnesium salt monohydrate; 2-propylpentanoic acid (3:2) magnesium salt; 2-propylpentanoic acid (4:3) magnesium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) magnesium salt xH2O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) calcium salt; 2-propylpentanoic acid (2:1) calcium salt monohydrate; 2-propylpentanoic acid (3:2) calcium salt; 2-propylpentanoic acid (4:3) calcium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) calcium salt xH2O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) strontium salt; 2-propylpentanoic acid (2:1) strontium salt monohydrate; 2-propylpentanoic acid (3:2) strontium salt; 2-propylpentanoic acid (4:3) strontium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) strontium salt xH2O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) barium salt; 2-propylpentanoic acid (2:1) barium salt monohydrate; 2-propylpentanoic acid (3:2) barium salt; 2-propylpentanoic acid (4:3) barium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) barium salt xH2O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two.
The Examples which follow illustrate the invention.
EXAMPLE 1
144.21 g (1 mol) of liquid valproic acid and an alkali metal carbonate or alkaline earth metal carbonate in the amounts indicated in Table 1 are placed in a round-bottom flask equipped with a stirrer, a reflux condenser and a heater. The mixture is stirred and heated slowly to a temperature above 100° C. (>100° C.), the reaction starting with the formation of CO2 and water. The CO2 and water formed are removed continuously, the CO2 escaping in gaseous form and the water formed being distilled over a descending column. When the reaction has ended, a clear product is obtained which is recovered via a melting plate. The water content of the resulting product is determined by the Karl-Fischer method and the water deficiency is made up if a particular hydrate is to be prepared.
TABLE 1
Carbonate/ Water
bicarbonate used (gram,
Exp. Valproic acid (gram, gram,
no. (gram, mol) gram equivalent) equivalent) (m + n):m
1 144.21 g, Na2CO3 0 3:2
1.0 mol (35.33 g, 0.33 mol)
2 144.21 g, Na2CO3 0 5:3
1.0 mol (31.80 g, 0.30 mol)
3 144.21 g, Na2CO3 (4.50 g, 4:3
1.0 mol (39.75 g, 0.38 mol) 0.25 mol)
4 144.21 g, K2CO3 0 2:1
1.0 mol (34.55 g, 0.25 mol)
5 144.21 g, Rb2CO3 0 2:1
1.0 mol (57.74 g, 0.25 mol)
6 144.21 g, NaHCO3 0 2:1
1.0 mol (42.01 g, 0.50 mol)
The samples were subjected to elemental analysis. Also, phase analysis was carried out by means of X-ray diffraction (XRD) on powder preparations. Examples of such analyses are as follows:
2-Propylpentanoic acid (4:3) sodium salt monohydrate (OMNIVAL I)
triclinic unit cell: figure of merit M = 12.6
ao = 15.9 bo = 13.5 co = 5.4
alpha = 101° beta = 97° gamma = 111°
cell volume 1025
5 molecules in the unit cell give an X-ray density of 1.27 g/cm3.
2-Propylpentanoic acid (3:2) sodium salt (OMNIVAL II)
triclinic unit cell: figure of merit M = 5.4
ao = 15.5 bo = 13.0 co = 10.4
alpha = 89° beta = 93° gamma = 110°
cell volume 1973
9 molecules in the unit cell give an X-ray density of 1.20 g/cm3.

Claims (14)

What is claimed is:
1. Method of preparing compounds containing at least one molecule of valproic acid salt and at least one molecule of valproic acid, comprising:
selecting an amount of alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, or combinations thereof;
selecting an amount of valproic acid;
combining the valproic acid directly with the selected amount of alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, or combinations thereof to form a reaction mixture;
reacting valproic acid directly with the selected amount of alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, or combinations thereof in the absence of a solvent; and
controlling a reaction temperature above the melting point of the valproic acid;
wherein the valproic acid salt is an alkali metal or alkaline earth metal salt.
2. Method according to claim 1, wherein the reaction temperature is from about 50° C. to about 250° C.
3. Method according to claim 1, wherein the reaction temperature is from about 70° C. to 180° C.
4. Method according to claim 1, further comprising the step of continuously removing carbon dioxide and water, which are formed during the step of reacting the valproic acid directly with the selected amount of alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, or combinations thereof in the absence of a solvent, from the reaction mixture.
5. Method according to claim 1, further comprising the step of adding an amount of water to the reaction mixture to form a hydrate after the step of reacting the valproic acid directly with the selected amount of alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, or combinations thereof in the absence of a solvent.
6. Method according to claim 1, wherein the alkali metal salt of valproic acid is a lithium, a sodium, a potassium or a rubidium salt.
7. Method according to claim 1, wherein the alkali metal salt of valproic acid is a sodium or a potassium salt.
8. Method according to claim 1, wherein the alkaline earth metal salt of valproic acid is a magnesium, calcium, strontium or barium salt.
9. Method according to claim 1, wherein the alkaline earth metal salt of valproic acid is a magnesium or a calcium salt.
10. Method according to claim 1, wherein a compound of general formula (I):
[(CH3CH2CH2)2CH—C(O)OMe]m.[(CH3CH2CH2)2CH—C(O)OH]n.xH2O  (I)
is prepared in which
Me is Li+, Na+, K+, Rb+, Mg2+, Ca2+, Sr2+ or Ba2+;
m is an integer from 1 to 10,
n is an integer from 1 to 9,
and the ratio m:n is from 1:1 to 6:1; and
x is zero, 1 or 2.
11. Method according to claim 10, wherein
Me is Na+, K+, Mg2+ or Ca2+;
m is an integer from 1 to 6,
n is an integer from 1 to 3,
and the ratio m:n is from 1:1 to 5:3; and
x is zero or 1.
12. Method according to claim 10, wherein the ratio m:n is about 1:1, about 4:3 or about 2:1.
13. Method according to claim 1, wherein a compound of 2-propylpentanoic acid (3:2) sodium salt of the formula
[(CH3CH2CH2)2CH—C(O)OMe]2.[(CH3CH2CH2)2CH—C(O)OH]
is prepared.
14. Method according to claim 1, wherein a compound of 2-propylpentanoic acid (4:3) sodium salt monohydrate of the formula
[(CH3CH2CH2)2CH—C(O)OMe]3.[(CH3CH2CH2)2CH—C(O)OH].H2O
is prepared.
US10/129,023 1999-11-02 2000-10-31 Method of preparing valproinic acid compounds Expired - Fee Related US6753349B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1997/99 1999-11-02
CH199799 1999-11-02
PCT/CH2000/000578 WO2001032595A1 (en) 1999-11-02 2000-10-31 Method for producing compounds of the valproinic acid

Publications (1)

Publication Number Publication Date
US6753349B1 true US6753349B1 (en) 2004-06-22

Family

ID=4223488

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/129,023 Expired - Fee Related US6753349B1 (en) 1999-11-02 2000-10-31 Method of preparing valproinic acid compounds

Country Status (7)

Country Link
US (1) US6753349B1 (en)
EP (1) EP1230205B1 (en)
AT (1) ATE284376T1 (en)
AU (1) AU7897400A (en)
CA (1) CA2387958C (en)
DE (1) DE50008920D1 (en)
WO (1) WO2001032595A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083063A1 (en) * 2005-10-07 2007-04-12 Nelson Deanna J Methods for the preparation and formulation of magnesium valproate hydrate
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
US20110040122A1 (en) * 2009-08-11 2011-02-17 Sci Pharmtech, Inc. Method for preparing metal salt of valproic acid
CN111349003A (en) * 2018-12-20 2020-06-30 四川科瑞德制药股份有限公司 Preparation method of sodium valproate
CN114853595A (en) * 2022-06-01 2022-08-05 广州茂丰药业有限公司 Preparation method of sodium valproate and valproic acid eutectic crystal and product thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007004238A2 (en) * 2005-07-06 2007-01-11 Morepen Laboratories Limited A process for the manufacture of divalproex sodium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE215533C (en)
US4895873A (en) 1987-03-20 1990-01-23 Desitin Arzenimittel GmbH Calcium salt of valproic acid
US5017613A (en) 1983-07-20 1991-05-21 Sanofi, S. A. Valproic acid preparations
US5795615A (en) 1994-09-30 1998-08-18 Kemin Industries, Inc. Process for producing metal carboxylates for use as animal feed supplements
US6077542A (en) * 1995-02-02 2000-06-20 Sherman; Bernard Charles Solid substances comprising valproic acid and sodium valproate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063328D1 (en) * 1979-08-20 1983-07-07 Abbott Lab Mixed salt of valproic acid
DD215533A1 (en) * 1983-05-24 1984-11-14 Dresden Arzneimittel PROCESS FOR THE PREPARATION OF NEW ALKALI AND ERDALCALISALES OF DI-N-PROPYL ACIDIC ACID

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE215533C (en)
US5017613A (en) 1983-07-20 1991-05-21 Sanofi, S. A. Valproic acid preparations
US4895873A (en) 1987-03-20 1990-01-23 Desitin Arzenimittel GmbH Calcium salt of valproic acid
US5795615A (en) 1994-09-30 1998-08-18 Kemin Industries, Inc. Process for producing metal carboxylates for use as animal feed supplements
US6077542A (en) * 1995-02-02 2000-06-20 Sherman; Bernard Charles Solid substances comprising valproic acid and sodium valproate

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083063A1 (en) * 2005-10-07 2007-04-12 Nelson Deanna J Methods for the preparation and formulation of magnesium valproate hydrate
US7482486B2 (en) * 2005-10-07 2009-01-27 Biolink Life Sciences, Inc. Methods for the preparation and formulation of magnesium valproate hydrate
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
WO2011011376A3 (en) * 2009-07-20 2011-05-19 Biolink Life Sciences, Inc. Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine
US20110040122A1 (en) * 2009-08-11 2011-02-17 Sci Pharmtech, Inc. Method for preparing metal salt of valproic acid
US8729300B2 (en) 2009-08-11 2014-05-20 Sci Pharmtech, Inc. Method for preparing metal salt of valproic acid
CN111349003A (en) * 2018-12-20 2020-06-30 四川科瑞德制药股份有限公司 Preparation method of sodium valproate
CN111349003B (en) * 2018-12-20 2023-10-03 四川科瑞德制药股份有限公司 Preparation method of sodium valproate
CN114853595A (en) * 2022-06-01 2022-08-05 广州茂丰药业有限公司 Preparation method of sodium valproate and valproic acid eutectic crystal and product thereof
CN114853595B (en) * 2022-06-01 2024-04-26 广州茂丰药业有限公司 Preparation method of sodium valproate and valproic acid eutectic and product thereof

Also Published As

Publication number Publication date
EP1230205B1 (en) 2004-12-08
ATE284376T1 (en) 2004-12-15
WO2001032595A1 (en) 2001-05-10
CA2387958A1 (en) 2001-05-10
AU7897400A (en) 2001-05-14
CA2387958C (en) 2010-02-02
DE50008920D1 (en) 2005-01-13
EP1230205A1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
EP0143271B1 (en) Acid salts of valproic acid
JP2005508379A (en) Method for producing formate formate
KR20110124317A (en) High yield and rapid syntheses methods for producing metallo-organic salts
JP6160621B2 (en) Pyrroloquinoline quinone tetraalkali salt and crystal thereof, production method thereof, and composition
US6753349B1 (en) Method of preparing valproinic acid compounds
CZ301968B6 (en) Plant growth regulator compositions
EP0034172B1 (en) Mixed salt of valproic acid
US6232497B1 (en) Method for producing alkali metal and alkaline earth metal pyruvates
RU2020964C1 (en) Method for preparing potassium fluoride peroxyhydrate used as decontaminating and disinfecting medicine
US3947491A (en) Stabilized choline salicylate compounds
EP0141267B1 (en) Acid salts of valproic acid
US3855282A (en) Stabilized choline salicylate compounds
CN100398547C (en) Process for producing 3-chloromethyl-3-cephem derivative
US4147776A (en) Stabilized choline salicylate compounds
JP2004075413A (en) Method for manufacturing hexafluoro phosphate complex, synthesized product, hexafluoro phosphate and its manufacturing method
JP2961457B2 (en) Method for producing fluorinated organic quaternary ammonium salts
CA1290761C (en) Chemical complex of potassium acetylsalicylate and preparation thereof
JPH04261189A (en) Production of tin trifluoromethanesulfonate
KR20000010726A (en) Soluble magnesium catalyst for producing dihydroxy esther
KR101203037B1 (en) High yield and rapid syntheses methods for producing metallo-organic salts
RU2099058C1 (en) Method of preparing the solid quick-soluble dispersed system containing acetylsalicylic acid
KR900003530B1 (en) Crystalline salts of l or (s)-3-(3,4-dihydroxyphenyl)-2-methyl alanine esters and process
SU1054292A1 (en) Method for preparing borohydrine x complexes of rare-earth elements
SK280602B6 (en) Polynuclear complex compounds of magnesium with aminodicarboxylic acids, halogen, process of their preparation
US646631A (en) Phenol ether of quinin carbonic acid.

Legal Events

Date Code Title Description
AS Assignment

Owner name: CILAG AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEH, CHRISTIAN;REEL/FRAME:013205/0215

Effective date: 20020523

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20160622